Skip to main content

Advertisement

Table 2 Polymorphisms in lipid metabolizing genes and risk of CKD

From: Polymorphisms of genes involved in lipid metabolism and risk of chronic kidney disease in Japanese - cross-sectional data from the J-MICC study

Polymorphism Genotype CKD (+) CKD (-) Per allele P
   (n = 564) (n = 2,704) aOR (95% CI)*  
APOA1 Ala61Thr (G219A) G/G 506 (89.7%) 2,423 (89.6%)   
(rs12718465) A/G 56 (9.9%) 268 (9.9%) 0.98 (0.74-1.31) 0.901
  A/A 2 (0.4%) 13 (0.5%)   
APOA5 G553T (Cys185Gly) G/G 483 (85.6%) 2,375 (87.8%)   
(rs2075291) G/T 79 (14.0%) 309 (11.4%) 1.12 (0.87-1.43) 0.378
  T/T 2 (0.4%) 20 (0.7%)   
APOA5 T-1131C T/T 221 (39.2%) 1,197 (44.3%)   
(rs662799) C/T 258 (45.7%) 1,183 (43.8%) 1.22 (1.06-1.39) 0.004
  C/C 85 (15.1%) 324 (12.0%)   
APOA5 C/A C/C 210 (37.2%) 1,028 (38.0%)   
(rs6589567) C/A 264 (46.8%) 1,241 (45.9%) 1.03 (0.90-1.17) 0.684
  A/A 90 (16.0%) 435 (16.1%)   
APOA5 T1259C T/T 282 (50.0%) 1,437 (53.1%)   
(rs2266788) T/C 224 (39.7%) 1,059 (39.2%) 1.19 (1.03-1.37) 0.019
  C/C 58 (10.3%) 208 (7.7%)   
APOB A/G A/A 308 (54.6%) 1,421 (52.6%)   
(rs673548) A/G 210 (37.2%) 1,056 (39.1%) 0.95 (0.82-1.10) 0.490
  G/G 46 (8.2%) 227 (8.4%)   
APOE Arg158Cys (C609T) C/C 523 (92.7%) 2,472 (91.4%)   
(rs7412) C/T 40 (7.1%) 226 (8.4%) 0.82 (0.58-1.15) 0.255
  T/T 1 (0.2%) 6 (0.2%)   
APOE Cys112Arg (T471C) T/T 469 (83.2%) 2,200 (81.4%)   
(rs429358) T/C 88 (15.6%) 466 (17.2%) 0.91 (0.73-1.13) 0.388
  C/C 7 (1.2%) 38 (1.4%)   
APOE T-219G T/T 290 (51.4%) 1,317 (48.7%)   
(rs405509) T/G 228 (40.4%) 1,090 (40.3%) 0.90 (0.78-1.03) 0.124
  G/G 46 (8.2%) 297 (11.0%)   
APOE cluster A/G A/A 452 (80.1%) 2,155 (79.7%)   
(rs4420638) A/G 104 (18.4%) 509 (18.8%) 0.97 (0.79-1.20) 0.798
  G/G 8 (1.4%) 40 (1.5%)   
TOMM40 A/G A/A 118 (20.9%) 825 (30.5%)   
(rs157580) A/G 299 (53.0%) 1,257 (46.5%) 1.27 (1.12-1.45) <0.001
  G/G 147 (26.1%) 622 (23.0%)   
HMGCR G/A G/G 163 (28.9%) 736 (27.2%)   
(rs3846662) G/A 278 (49.3%) 1,326 (49.0%) 0.91 (0.80-1.04) 0.162
  A/A 123 (21.8%) 642 (23.7%)   
LPL G/A G/G 366 (64.9%) 1,797 (66.5%)   
(rs331) G/A 177 (31.4%) 816 (30.2%) 1.04 (0.88-1.22) 0.681
  A/A 21 (3.7%) 91 (3.4%)   
LPL G1791C (Ser474Stop) G/G 423 (75.0%) 2,083 (77.0%)   
(rs328) G/C 131 (23.2%) 579 (21.4%) 1.07 (0.89-1.30) 0.466
  C/C 10 (1.8%) 42 (1.6%)   
NR1H3 G/A G/G 301 (53.4%) 1,512 (55.9%)   
(rs7120118) G/A 224 (39.7%) 1,027 (38.0%) 1.12 (0.97-1.31) 0.125
  A/A 39 (6.9%) 165 (6.1%)   
NR1H3 A/G A/A 299 (53.0%) 1,524 (56.4%)   
(rs2167079) A/G 227 (40.2%) 1,017 (37.6%) 1.14 (0.99-1.33) 0.078
  G/G 38 (6.7%) 163 (6.0%)   
MTNR1B A/G A/A 250 (44.3%) 1,245 (46.0%)   
(rs1447352) A/G 247 (43.8%) 1,176 (43.5%) 1.06 (0.92-1.22) 0.392
  G/G 67 (11.9%) 283 (10.5%)   
FADS2 C/T C/C 227 (40.2%) 979 (36.2%)   
(rs174570) C/T 250 (44.3%) 1,266 (46.8%) 0.91 (0.80-1.04) 0.167
  T/T 87 (15.4%) 459 (17.0%)   
KCNJ11 A1577G (Ile337Val) A/A 240 (42.6%) 1,068 (39.5%)   
(rs5215) A/G 241 (42.7%) 1,274 (47.1%) 0.95 (0.83-1.09) 0.485
  G/G 83 (14.7%) 362 (13.4%)   
TMEM57 A/G A/A 256 (45.4%) 1,186 (43.9%)   
(rs10903129) A/G 254 (45.0%) 1,234 (45.6%) 0.90 (0.78-1.04) 0.168
  G/G 54 (9.6%) 284 (10.5%)   
DOCK7 A/C A/A 347 (61.5%) 1,542 (57.0%)   
(rs1167998) A/C 188 (33.3%) 996 (36.8%) 0.86 (0.74-1.01) 0.061
  C/C 29 (5.1%) 166 (6.1%)   
CELSR2 C/T C/C 516 (91.5%) 2,413 (89.2%)   
(rs4970834) C/T 46 (8.2%) 280 (10.4%) 0.79 (0.58-1.07) 0.133
  T/T 2 (0.4%) 11 (0.4%)   
LIPC Val95Met (G340A) G/G 342 (60.6%) 1,616 (59.8%)   
(rs6078) G/A 193 (34.2%) 945 (34.9%) 0.96 (0.82-1.13) 0.643
  A/A 29 (5.1%) 143 (5.3%)   
LIPC T-514C T/T 132 (23.4%) 731 (27.0%)   
(rs1800588) T/C 290 (51.4%) 1,353 (50.0%) 1.10 (0.97-1.26) 0.143
  C/C 142 (25.2%) 620 (22.9%)   
CETP TaqIB (G > A) G/G 234 (41.5%) 934 (34.5%)   
(rs708272) G/A 251 (44.5%) 1,315 (48.6%) 0.81 (0.71-0.92) 0.002
  A/A 79 (14.0%) 455 (16.8%)   
CETP G/T G/G 372 (66.0%) 1,692 (62.6%)   
(rs3764261) G/T 170 (30.1%) 872 (32.2%) 0.86 (0.73-1.01) 0.068
  T/T 22 (3.9%) 140 (5.2%)   
CETP Ile405Val (G > A) G/G 147 (26.1%) 753 (27.8%)   
(rs5882) G/A 277 (49.1%) 1,312 (48.5%) 1.06 (0.93-1.20) 0.403
  A/A 140 (24.8%) 639 (23.6%)   
CETP A-629C A/A 162 (28.7%) 825 (30.5%)   
(rs1800775) A/C 279 (49.5%) 1,366 (50.5%) 1.10 (0.96-1.25) 0.174
  C/C 123 (21.8%) 513 (19.0%)   
  1. *aOR: adjusted odds ratio (adjusted for age and sex); 95% CI: 95% confidence interval; CKD: chronic kidney disease.